Bulliard, Yannick
Andersson, Borje S.
Baysal, Mehmet A.
Damiano, Jason
Tsimberidou, Apostolia M.
Funding for this research was provided by:
US National Institutes of Health/National Cancer Institute award number (P30 CA016672)
Article History
Received: 24 August 2023
Accepted: 12 October 2023
First Online: 25 October 2023
Declarations
:
: Not applicable.
: The authors permit the Journal of Hematology and Oncology to publish this work.
: A.M.T declares receipt of clinical trial research funding (to The University of Texas MD Anderson Cancer Center) from OBI Pharma, Agenus, IMMATICS, Tachyon, Novocure, Parker Institute for Cancer Immunotherapy, Orionis, Tempus, and Tvardi; fees for consulting; or advisory roles for Avstera Therapeutics, Bioeclipse, BrYet, Diaccurate, Macrogenics, NEX-I and VinceRx. Y.B is Employee of Appia Bio. J.D is Employee of Appia Bio. The remaining authors declare no relevant conflict of interest.